

RECEIVED
CENTRAL FAX CENTER
JUL 21 2006

Attorney Docket No.: 6511.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Polisetti et al.

Application No.: 10/679,887

Group Art Unit: 1626

Filed: October 6, 2003

Examiner: Lambkin, Deborah C.

For: Aryl Carbonyl Derivatives as Therapeutic Agents

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references other than the one listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609.

The reference is as follows:

1. US Patent No. 5,556,969

07/24/2006 TL0111 00000039 141447 10679887
02 FC:1886 180.00 DA

Attorney Docket No.: 6511.204-US
Serial No.:
Filed: 10/679,887
Inventors: Polisetti et al.

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached reference.

This information disclosure statement is being filed after the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: July 21, 2006


Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

CUSTOMER NUMBER

23650

PATENT TRADEMARK OFFICE

Sheet 1 of 3

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6511.204-US	Serial No. 10/679,887
		Applicant Pollsettl et al.	
		Filing Date October 6, 2003	Group To be assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,556,969	9/17/1996	Chambers et al.	540	509	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.